Apexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult to treat diseases. The company's proprietary technology platform enables the discovery and development of superior antibody product candidates that are able to impact previously inaccessible disease targets. Apexigen is actively pursuing product development, both by itself and in collaboration with partners. The company's product portfolio is comprised of humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. Apexigen's technology platform and product pipeline have been validated by a number of partnerships representing both product development and antibody technology collaborations.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/06/13 | $20,000,000 | Series A-1 |
Amkey Ventures Sycamore Ventures Themes Investment Partners WSR Capital | undisclosed |
| 08/09/18 | $73,000,000 | Venture |
3E Bioventures Decheng Capital SV Tech Ventures Virtus Inspire Ventures | undisclosed |
| 03/24/20 | $65,000,000 | Series C Extension |
Decheng Capital Oceanpine Capital | undisclosed |
